Compare Baroda BNP Paribas Health and Wellness Fund vs UTI Healthcare Fund
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹500 | ₹500 |
Expense Ratio | 2.33 | 2.27 |
NAV | ₹9.32 | ₹275.66 |
Fund Started | 09 Jun 2025 | 01 Aug 2005 |
Fund Size | ₹611.32 Cr | ₹1101.63 Cr |
Exit Load | Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year. | Exit load of 1% if redeemed within 30 days. |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹500
₹500
Expense Ratio
2.33
2.27
NAV
₹9.32
₹275.66
Fund Started
09 Jun 2025
01 Aug 2005
Fund Size
₹611.32 Cr
₹1101.63 Cr
Exit Load
Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
Exit load of 1% if redeemed within 30 days.
1 Year | - | -0.39% |
3 Year | - | 23.21% |
5 Year | - | 14.00% |
1 Year
-
-0.39%
3 Year
-
23.21%
5 Year
-
14.00%
Equity | 96.78% | 99.40% |
Cash | -0.31% | 0.59% |
Equity
96.78%
99.40%
Cash
-0.31%
0.59%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 8.99% |
Mankind Pharma Ltd. | 7.00% |
Cipla Ltd. | 6.51% |
Max Healthcare Institute Ltd. | 6.28% |
Apollo Hospitals Enterprise Ltd. | 6.00% |
Aster DM Healthcare Ltd. | 4.90% |
Abbott India Ltd. | 4.82% |
Divi's Laboratories Ltd. | 4.24% |
Torrent Pharmaceuticals Ltd. | 3.96% |
Astrazeneca Pharma India Ltd. | 3.84% |
Sun Pharmaceutical Industries Ltd. | 9.37% |
Ajanta Pharma Ltd. | 7.16% |
Lupin Ltd. | 5.65% |
Glenmark Pharmaceuticals Ltd. | 4.06% |
Gland Pharma Ltd. | 3.60% |
Procter & Gamble Health Ltd. | 3.46% |
Dr. Reddy's Laboratories Ltd. | 3.46% |
Cipla Ltd. | 3.43% |
Alkem Laboratories Ltd. | 3.40% |
Apollo Hospitals Enterprise Ltd. | 3.39% |
Name | Sanjay Chawla | - |
Start Date | 09 Jun 2025 | - |
Name
Sanjay Chawla
-
Start Date
09 Jun 2025
-
Description | The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. |
Launch Date | 09 Jun 2025 | 01 Aug 2005 |
Description
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Launch Date
09 Jun 2025
01 Aug 2005